Inhibitors of folic acid synthesis were compared alone and in different combinations in the therapy of pneumocystosis in immunosuppressed rats. Sulfonamides (sulfamethoxazole, sulfadiazine, and sulfadoxine) and sulfones (dapsone) used alone were very active against Pneumocystis carinii, as judged by histologic examination of the lungs and by organism quantitation. Improved efficacy could not be demonstrated by the addition of an inhibitor of dihydrofolate reductase to the regin1en. Dihydrofolate reductase inhibitors (trimethoprim, diaveridine, and pyrimethamine) used alone were ineffective against P. carinii. All drugs were well tolerated except pyrimethamine, which caused bone marrow depression; folinic acid ameliorated this adverse reaction but did not interfere with P. carinii treatment. These data have potential clinical implications but need to be interpreted with caution and in light of other systems of P. carinii drug evaluation.
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Although Pneumocystis carinii has long been recognized as an important opportunistic pulmonary pathogen (36) , the organism has presented new clinical challenges in patients with the acquired immunodeficiency syndrome (AIDS). Pneumocystosis in AIDS is characterized by subtle presentation, slow response to therapy, frequent relapse, and a high rate of adverse drug reactions (10, 12, 23, 34) . Inhibitors of folic acid synthesis have been a major form of P. carinii treatment. Attention has focused on the use of an inhibitor of dihydrofolate reductase (DHFR) (primarily trimethoprim) in combination with a sulfonamide (mainly sulfamethoxazole) (6, 13, 14, 21, 33, 40) . Other DHFR inhibitors used in the treatment of clinical and experimental pneumocystosis have included pyrimethamine, tetroxoprim, pitrexim, and trimetrexate; sulfonamides and sulfones have included sulfadiazine, sulfadoxine, sulfamonomethoxine, dapsone, and sulfonylbisformanilide (1, 7, 9, 15-18, 20, 24-26, 29, 30, 39, 41, 42, 43) .
Little is known about the relative efficacy and toxicity of the different folic acid inhibitors in the treatment of P. carinii, yet such information is important in developing new forms of therapy. In vitro approaches to drug development have involved analysis of the effects of antimicrobial agents on P. carinii growth in tissue culture or the uptake of dyes or radiolabeled compounds by nonreplicating organisms or by enzyme preparations (1, 2, 4, 27, 28) . In vivo studies, which have been much more widely used, have been based on an animal model in which rats immunosuppressed with corticosteroids spontaneously develop pneumocystosis with histologic features identical to those of the disease in humans; drugs which are active against rat P. carinii have usually shown activity against human P. carinii (9, 14, 15) . We have developed histologic and quantitative techniques to evaluate the extent of P. carinii pneumonia in immunosuppressed rats and to monitor the efficacy of therapy (3, 4, 5, 19, 37) . In the present report, we have used these procedures to compare folic acid inhibitors, alone and in various combinations, in the treatment of experimental pneumocystosis. * Corresponding author.
MATERIALS AND METHODS
Experimental design. The basic animal protocol has been described in detail in our previous studies (19, 37) . Adult male Sprague-Dawley rats obtained from Harlan Industries, Madison, Wis., weighing about 250 g, were used in the study. After a period of acclimation in a conventional colony room, the animals were administered an immunosuppressive regimen of 25 mg of cortisone acetate (Cortone; Merck Sharp & Dohme, West Point, Pa.) injected subcutaneously twice weekly or 4 mg of methylprednisolone acetate (DepoMedrol; The Upjohn Co., Kalamazoo, Mich.) injected subcutaneously once weekly, a low (8%) protein diet (Bioserv, Frenchtown, N.J.), and tetracycline powder (Polyotic; American Cyanamid, Wayne, N.J.) (1 mg/ml) in the drinking water to induce pneumocystosis. The rats were weighed regularly, and a few animals were sacrificed periodically to monitor the development of the disease. After 5 to 6.5 weeks, when P. carinii infection had reached moderate intensity, the animals were randomly divided into different treatment groups of about 16 rats each. Antimicrobial agents to be tested were administered for 3 weeks, during which time all rats remained on the immunosuppressive regimen. Control rats on this steroid immunosuppressive protocol received tio therapy; pilot studies revealed no differences in the extent of P. carinii pneumonia among these animals or among rats administered a placebo (solution used to deliver the drugs). Also included as controls were normal rats which ate a regular diet, drank plain tap water, and received no medications. At the end of the treatment period, the rats were sacrificed by an overdose of halothane anesthesia. The drugs were prepared as a liquid suspension and administered on a milligram-per-kilogram basis as a single daily dose by oral gavage. The dose was based on the average weight of the rats (about 150 g) at the beginning of treatment and remained the same over the 3-week course of therapy. In some experiments, the dose of pyrimethamine had to be reduced because of bone marrow depression; 1 mg of folinic acid was injected subcutaneously each day in an attempt to prevent this adverse effect. The hematologic effects of pyrimethamine were monitored by performing complete blood counts on peripheral blood of rats receiving the drug and comparing the results with data obtained in animals not receiving the drug.
Evaluation of P. carinii therapy. Therapy was complicated by the fact that the rats, which were heavily immunosuppressed and chronically debilitated, were very susceptible to other opportunistic infections and to the toxic effects of drugs; animals frequently died before completion of treatment for P. carinii. Therefore, assessment of drug efficacy was based on the extent of pneumocystosis in the lungs rather than on animal survival (19) . P. carinii infection in the drug-treated rats was compared with that in controls in the same experiment; when a compound was evaluated in more than one experiment, the control groups were pooled. Our preliminary studies suggested that 10 days was sufficient to observe a therapeutic response; unless otherwise stated, only rats which received .10 days of anti-P. carinii treatment were included in the data analysis.
Assessment of P. carinii pneumonia in the lungs was based on histologic and quantitative procedures previously reported in detail (3, 4, 5, 19, 37 Our previous study demonstrated that the histologic scoring system and cyst and nuclei counts provided comparable assessment of drug therapy of P. carinii pneumonia (19) . In the present report, lung specimens of all animals were examined histologically, whereas the quantitation studies were performed on about six rats from each treatment group. Since the changes in cyst and nuclei counts after therapy were similar, only the cyst data have been presented in detail here; nuclei counts have been included on a selective basis to illustrate the changes resulting from therapy. Sulfadoxine. The activity of sulfadoxine against rat P. carinii was similar to that of sulfamethoxazole or sulfadiazine (Fig. 3) Fig. 1 for other abbreviations. used by other workers (15) (Fig. 4) . Rats Further studies with pyrimethamine. Studies were then performed with lower doses of pyrimethamine and folinic acid in an attempt to ameliorate the bone marrow depression (Fig. 6 and 7) . One approach involved administering pyrimethamine in a dose of 3 mg/kg per day alone or in combination with a sulfonamide. The other approach involved administering pyrimethamine in a dose of 9 mg/kg per day and folinic acid at 1 mg per day alone or in combination with a sulfonamide; however, because of ongoing hematologic problems, the pyrimethamine dose was reduced to 6 mg/kg per day. Both regimens permitted the rats to survive long enough (median duration of therapy was usually 14 to 18 days) to assess drug efficacy.
Pyrimethamine administered alone in the dose of 3 mg/kg per day or in the dose of 9 mg/kg per day to 
DISCUSSION
The present study has compared different inhibitors of folic acid synthesis in the treatment of pneumocystosis. The data indicate that sulfonamides used alone are highly active against P. carinii. Comparable results were achieved with 250 mg/kg per day of sulfamethoxazole, sulfadiazine, or sulfadoxine, and efficacy was not enhanced by the addition of a DHFR inhibitor to the regimen. That these data are truly reflective of drug activity is suggested by the fact that dosage was controlled, and the extent of pneumocystosis was evaluated by both histologic and quantitative techniques. Sulfamethoxazole administered at a dose of 62.5 mg/kg per day was also quite active against P. carinii, and its effectiveness was not materially improved when combined with trimethoprim. Thus, it appears that further reduction in drug dose or alteration in experimental design will be needed to clearly demonstrate a synergistic effect between a sulfonamide and a DHFR inhibitor in this animal model.
There has been little apparent interest in studying the use of sulfonamides as single-agent therapy for clinical or experimental pneumocystosis. One previous report found that the combination of pyrimethamine and sulfadiazine was more active against P. carinii than was either agent used alone in limited numbers of rats (14) . In contrast, there have been numerous studies of the relative efficacy of sulfonamides used alone or in combination with a -DHFR inhibitor in experimental models of other protozoa (e.g., Toxoplasma gondii) (8, 11, 22, 31, 35) . It has sometimes been difficult to demonstrate a synergistic effect of combination therapy for toxoplasmosis in mice, depending on such factors as the specific drug used, dose, or route of administration; in addition, differences in drug metabolism or pharmacology have made it difficult to extrapolate from data obtained in these animals to humans. In such cases, in vitro systems might provide a better measure of drug interaction (11) .
In the present study, dapsone used alone exhibited doserelated activity against P. carinii which was not improved by the addition of a DHFR inhibitor. Our rats were heavily immunosuppressed and malnourished, and pneumocystosis was already moderately far advanced before treatment was begun. This system was designed to mimic the situation in AIDS and might not be sensitive enough to detect subtle effects of drug interactions. In previous reports, the combination of a sulfone and trimethoprim was no more effective 6 . Treatment of pneumocystosis with pyrimethamine and other drugs as assessed by histologic score. Pyrimethamine was administered either in the dose of 3 mg alone or in the dose of 9 mg reduced to 6 mg together with folinic acid (1 mg). These basic regimens were then combined with sulfonamides or sulfones in the following manner: Pyrimethamine-sulfamethoxazole (62.5 mg); pyrimethamine-sulfamethoxazole (250 mg); pyrimethamine-folinic acid-sulfamethoxazole (250 mg); pyrimethamine-sulfadiazine (250 mg); pyrimethamine-folinic acid-sulfadiazine (250 mg); pyrimethaminesulfadoxine (250 mg); pyrimethamine-folinic acid-sulfadoxine (250 mg); pyrimethamine-dapsone (15 mg); pyrimethamine-dapsone (125 mg); and pyrimethamine-folinic acid-dapsone (125 mg). All than the sulfone alone in therapy for well-established rat P. carinii pneumonia; however, with less immunosuppression, adjustment of sulfone dose, and earlier initiation of anti-P. carinii treatment, a synergistic effect could be demonstrated (15, 17) . Uncontrolled clinical studies have also suggested that the combination of trimethoprim and dapsone is more effective anti-P. carinii therapy than is dapsone used alone (25) .
In addition to the sulfonamides and sulfones, anti-P. carinii activity in the rat model has been found among selected sulfonylureas (16) . It will be important to design clinical trials so that different members of these classes of drugs can be compared in the treatment of pneumocystosis under controlled conditions; individual compounds differ considerably in their pharmacology and in the type and frequency of adverse reactions. Consideration should also be given to exploring the use of these agents without a DHFR inhibitor, since some cases of rash associated with trimethoprim-sulfamethoxazole may be associated with the trimethoprim component (24) .
As described in previous reports (9, 14, 21) , DHFR inhibitors used alone in the present study were ineffective treatment for pneumocystosis, and there were no differences noted among these compounds in anti-P. carinii activity when they were combined with a sulfonamide or sulfone. Trimethoprim and diaveridine were well tolerated by the rats, but pyrimethamine caused serious bone marrow depression. This adverse effect limited not only the dose but also the length of time for which pyrimethamine could be given. Our experience with folic acid inhibitors, as well as with other agents tested so far, suggests that the duration of therapy can be an important contributor to drug efficacy in the rat model of pneumocystosis.
All drugs in the present study were administered on a milligram-per-kilogram basis as a single daily dose by oral gavage. We feel that this method allows greater precision in drug dose than does mixing the compounds in the food or drinking water, as had been done in earlier studies. The method of drug administration has had no discernable impact on the activity of DHFR inhibitors when used alone but might have affected the results of the drug synergism experiments. Studies directly comparing methods of administration with drug pharmacokinetics and anti-P. carinii activity in the rat model will be necessary to answer these questions.
Recently, techniques have been developed to isolate rat P. carinii DHFR and to study the effects of antimicrobial drugs; a hierarchy in potency has been found among inhibitors of this enzyme with trimetrexate, an analog of methotrexate, being more potent than pyrimethamine, which is more potent than trimethoprim (1) . Based on this finding, trimetrexate has shown promising activity when used alone against rat and human pneumocystosis (7, 30) . Such information has important clinical implications, in light of the high frequency of toxic reactions to sulfonamides among AIDS patients (10, 23, 34, 38) . Controlled clinical trials comparing DHFR inhibitors alone or in combination with other drugs for activity against human P. carinii are needed; yet, based on our results obtained in the rat model, there would be little impetus to perform such studies if this system were the sole means of screening anti-P. carinii drugs.
The dramatic rise in the number of cases of P. carinji pneumonia associated with the spread of AIDS has stimulated efforts to develop new forms of therapy (25) . The rat model will continue to play an important role in this effort because it has usually been a reliable predictor of drug activity in humans (9, 14, 15) . The present study of folic acid inhibitors emphasizes that the rat model is complex and that data obtained should be carefully interpreted and correlated with other systems of drug evaluation. 
